BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
$7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th Management to host a conference call today at 8:30 a.m. ET DUBLI
DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 14 at 5:00 p.m. GMT / 12:00 p.m. ET.Piper Sandler 35th Annual Healthcare Conference: Fireside chat on Wednesday, November 29 at 11:30 a.m. ET
DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a
Oncoinvent AS: Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin in Colorectal Cancer Patients finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.